Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

By D. Michelson, D. Faries, J. Wernicke, D. Kelsey, Katherine Kendrick, F. Sallee, T. Spencer. Pediatrics, 2001

658 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Evidence-Based Psychosocial Treatments for Attention-Deficit/Hyperactivity Disorder (2008, background): “, 2001 (97, 1218)b 86% Caucasian, 9% Hispanic, 2% African American, 3% Asian 90 Reported 1,2,4,11 PhD clinical psychologists 1.”
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. (2007, background): “Subsequently, numerous large-scale clinical trials prove the efficacy of these new agents (Biederman et al., 2002; Greenhill et al., 2002, 2005; McCracken et al., 2003; Pelham et al., 1999; Wigal et al., 2005; Wolraich, 2000; Wolraich et al., 2001) and atomoxetine (Michelson et al., 2001, 2003).”
Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder (2002, background): “In children and adolescents, atomoxetine had superior outcomes in reducing ADHD symptoms compared with placebo and had a graded dose response (Michelson et al. 2001).”
Attention-Deficit/Hyperactivity Disorder in Adults (2004, background): “The first type of drug, atomoxetine, has an effect on norepinephrine systems alone [39,40].”